Synthetic THC May Calm Agitation in Alzheimer's Patients
By Carole Tanzer Miller HealthDay Reporter
MONDAY, Sept. 30, 2024 -- A synthetic form of the active ingredient in cannabis helps reduce agitation in people with Alzheimer's, new research shows.
Synthetic THC (dronabinol) also gave patients' caregivers a boost, according to findings presented Thursday at a meeting of the International Psychogeriatrics Association in Buenos Aires.
The findings may provide encouragement for the families of the 7 million Americans who have Alzheimer's or another form of dementia. Nine out of 10 develop behavior problems, and agitation is the most common, affecting 4 in 10.
Agitated patients with Alzheimer's often pace, wander, yell, scream and get verbally abusive. Their behavior may also leave their caregivers burned out and depressed.
"It is the agitation, not the memory loss, that often drives individuals with dementia to the emergency department and long-term care facilities," said study co-author Dr. Brent Forester, director of behavioral health for Tufts Medicine in Boston. "Dronabinol has the potential to both reduce health care costs and make an important, positive impact on caregivers' mental and physical health."
The new study included 75 outpatients with Alzheimer's dementia. For three weeks, they took either 5 milligrams (mg) of dronabinol twice a day or a dummy pill.
Symptoms of agitation were significantly improved in the patients who took dronabinol, and researchers said the drug was well-tolerated.
"Dronabinol appears to perform just as well, if not better, than the only other FDA-approved drug for agitation in this patient population currently on the market," Forester said.
A pilot study had suggested that cannabinoid therapies might be an effective way to treat agitation in people with dementias.
"While further analyses are needed to better understand predictors of treatment response to help inform subsequent trials and clinical practice, the early results are quite encouraging," Forester said in a Tufts news release.
Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-01 00:00
Read more
- Fatty Liver Disease Now Affects 4 in 10 U.S. Adults
- E. Coli Illnesses Linked to McDonald's Quarter Pounders Climb to 104
- ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
- Duodenal ReCET Plus Semaglutide Can Prevent Need for Insulin in T2DM
- Election Stressing You Out? An Expert Has Coping Tips
- Dating Apps Linked to More Hookups That Risk College Students' Health
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions